

Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit



Pauline E.R. Spronk^{a, b, *}, José H. Volders^c, Petrousjka van den Tol^c, Carolien H. Smorenburg^d, Marie-Jeanne T.F.D. Vrancken Peeters^e

^a Department of Surgery, Leiden University Medical Centre, Leiden, the Netherlands

^b Department of Research, Dutch Institute for Clinical Auditing (DICA), Leiden, the Netherlands

^c Department of Surgery, VU University Medical Centre, Amsterdam, the Netherlands

^d Department of Medical Oncology, Antoni van Leeuwenhoek, Amsterdam, the Netherlands

^e Department of Surgery, Antoni van Leeuwenhoek, Amsterdam, the Netherlands

ARTICLE INFO

Article history:

Received 8 August 2018

Received in revised form

30 August 2018

Accepted 5 September 2018

Available online 17 October 2018

Keywords:

Neoadjuvant chemotherapy

Breast conserving surgery

Involved margin rate

Re-excision rate

ABSTRACT

Introduction: NAC has led to an increase in breast conserving surgery (BCS) worldwide. This study aims to analyse trends in the use of neoadjuvant chemotherapy (NAC) and the impact on surgical outcomes. **Methods:** We reviewed all records of cT1–4N0–3M0 breast cancer patients diagnosed between July 2011 and June 2016 who have been registered in the Dutch National Breast Cancer Audit (NBCA) (N = 57,177). The surgical outcomes of 'BCS after NAC' were compared with 'primary BCS', using a multivariable logistic regression model.

Results: Between 2011 and 2016, the use of NAC increased from 9% to 18% and 'BCS after NAC' (N = 4170) increased from 43% to 57%. We observed an involved invasive margin rate (IMR) of 6,7% and a re-excision rate of 6,6%. As compared to 'primary BCS', the IMR of 'BCS after NAC' is higher for cT1 (12,3% versus 8,3%; $p < 0.005$), equal for cT2 (14% versus 14%; $p = 0.046$) and lower for cT3 breast cancer (28,3% versus 31%; $p < 0.005$). Prognostic factors associated with IMR for both 'primary BCS' as for 'BCS after NAC' are: lobular invasive breast cancer and a hormone receptor positive receptor status (all $p < 0,005$).

Conclusion: The use of NAC and the incidence of 'BCS after NAC' increased exponentially in time for all stages of invasive breast cancer in the Netherlands. This nationwide data confirms that 'BCS after NAC' compared to 'primary BCS' leads to equal surgical outcomes for cT2 and improved surgical outcomes for cT3 breast cancer. These promising results encourage current developments towards de-escalation of surgical treatment.

© 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Introduction

Neoadjuvant chemotherapy in breast cancer patients has resulted in an increased rate of breast conserving treatment (BCT) consisting of breast conserving surgery (BCS) and radiation treatment [1–3]. Due to down-staging of the tumour by NAC, patients who were initially planned for mastectomy could receive BCS.

The advantages of BCS compared to mastectomy obviously include less morbidity and thereby improved aspects of quality of life [3–5]. Another benefit of NAC includes the opportunity to de-

escalate surgical treatment of the axilla [6–8]. BCS after NAC introduces challenges as identification of original tumour location and monitoring tumour response using imaging [9,10]. The efficacy of NAC to downsize or achieve a pathologic complete response (pCR) has improved due to more efficient targeted drug regimens, and pCR rates of up to 60–80% in the triple negative and HR-/HER2+ subtypes are now being reached [11,12]. These promising results have led to challenging new trials investigating the potential of non-operative therapy for invasive breast cancer by utilizing accurate image-guided percutaneous biopsy to document pathologic complete response [13–15].

While improved breast imaging and the promising concept of non-operative therapy in patients that reach pCR after NAC are currently being investigated, surgical management with the

* Corresponding author. Department of surgery, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.

E-mail address: paulinespronk@gmail.com (P.E.R. Spronk).

primary goal to remove the (residual) tumour with clear margins is still the standard of care. In the present study, we analyse trends in the surgical performance after NAC for breast cancer in the Netherlands between 2012 and 2016 (1), we describe the surgical outcomes including margins and re-excision rates for BCS after NAC compared to primary BCS (2) and identify prognostic factors associated with involved margins for both groups (3).

Methods

The NBCA

The NABON Breast Cancer Audit (NBCA) is a multidisciplinary nationwide registry of all diagnostic and treatment modalities of patients who are surgically treated for newly diagnosed breast cancer in the Netherlands. All 89 hospitals in the Netherlands participating in breast cancer care participate in this nationwide registry. Data completeness of the NBCA is estimated to be at least 95%. Available data from the NBCA dataset include demographic variables (year of incidence, age), tumour variables (histologic subtype, clinical tumour stage, clinical nodal stage and hormone receptor status) and treatment variables (use of systemic therapy, radiotherapy and type of surgery). Furthermore, the volume and type of hospital is being registered. Hospital volume was based on the surgical volume, which was defined as the mean annual number of breast cancer surgeries during the period 2012–2016. The cut-off points of <150 and 300<, were based on those reported in a publication of the European Society of Breast Cancer Specialist (EUSOMA) [16]. Hospital type was described as academic, teaching and general. Academic hospitals are part of a university, and both academic and teaching hospitals provide medical training to surgical residents.

Data selection

Data records of patients aged 18–98 years diagnosed with cT1-4N0-3M0 invasive breast cancer between July 2011 and June 2016 were abstracted from the NBCA. We excluded patients with a prior cancer diagnosis or unknown timing of chemotherapy. Neoadjuvant chemotherapy (NAC) was defined as chemotherapy given within four weeks prior to surgery. In accordance with international guidelines, the Dutch national breast cancer guidelines indicate NAC for patients with locally advanced disease (stage III) and recommended it in patients with stage II disease with an indication for systemic treatment [17,18]. Trends in the use of NAC and the surgical performance after NAC during the years were analysed.

Surgical performance

Type of surgery (BCS or mastectomy) and the pathology report of the surgical specimen was derived from the NBCA database. Resection margins of the surgical specimen were defined according to the Dutch guidelines and in accordance with the definition of the quality indicator defined by the NBCA audit [19]. In the Dutch guidelines, the definition for focally involved margins for invasive breast cancer is described as residual tumour in the resection surface over a maximum length of 4 mm. More than focally involved margins is defined as residual tumour in the resection surface over more than 4 mm. According to the Dutch guidelines, focally involved margins do not mandate re-excision. In case of more than focally involved (positive) margins, a re-excision is indicated unless the positive margin is the dorsal margin and the fascia has been resected. In addition to radiation after BCS, a radiation therapy boost may be applied when one or more of the following indications is present: age <50 years, an estimated local recurrences risk $\geq 1\%$ per year, grade 3, positive tumour margins and lymph

vascular space invasion [20,21].

Statistical analysis

Statistical analysis was performed in PASW Statistics version 20 (SPSS inc Chicago, IL, USA). Descriptive analyses were used to report on the trends in the use of NAC and in the surgical outcomes after NAC. Bivariate comparisons of surgical outcomes of BCS with and without NAC were performed with chi-square tests. Secondly, a multivariable logistic regression model was used to determine which factors were independent associated for tumour involved margins in BCS with and without NAC. Statistical tests were 2-sided and statistical significance was defined as a *p* value < 0.05.

Results

Overall, 62,982 patients were diagnosed with cT1-4N0-3M0 invasive breast cancer in the Netherlands between July 2011 and June 2016, and registered in the NBCA registry. Patients with a prior cancer diagnosis (*N* = 5661) or unknown timing of chemotherapy (*N* = 144) were excluded for further analyses, resulting in data of 57,177 patients available for our study. Median age was 62 years (range 19–98) and most of the patients were diagnosed with a clinical tumour stage of cT1 (*N* = 34,678; 60.7%) or cT2 (*N* = 18,482; 32.3%), without nodal involvement (*N* = 47,512; 83.1%).

Primary surgery without NAC was performed in 85.8% of all patients (*N* = 49,712); of which 65% were treated with BCS (*N* = 32,305) and 35% with a mastectomy (*N* = 17,407). In 14.2% of patients NAC was applied before surgery (*N* = 8195); of which 50.9% were treated with BCS (*N* = 4170) and 49.1% with a mastectomy (*N* = 4025). Clinical-pathological and hospital characteristics of patients treated with NAC are shown in Table 1. Women who received NAC followed by BCS instead of a mastectomy tended to be older (>50 yrs of age), except of patients aged >70 years of age. Tumour characteristics associated with NAC followed by BCS are ductal invasive histologic subtype, no multifocality, a cT1-2 clinical tumour stage and cN0 disease (all *P* < 0.005).

Between 2011 and 2016, there were 37 general-, 43 teaching- and 9 academic hospitals in the Netherlands; divided into low-volume <150 (*N* = 44), mid-range 150-300 (*N* = 34) and high-volume 300< (*N* = 11) hospitals. NAC was most often applied in academic hospitals (26% NAC; *N* = 1517) compared to teaching- (13% NAC; *N* = 3991) and general hospitals (12% NAC; *N* = 2687). The type or volume of hospital is not associated with the type of surgery received after NAC [Table 1].

Trends in the surgical performance after NAC

In the last 5 years the use of NAC increased from 9% in 2012 to 18% in 2016 and applies to the clinical tumour stages cT1-3 [Table 2]. There is no increasing trend in the use of NAC for cT4 breast cancer (a stable percentage around 63% over the years). A greater upward trend per tumour stage in the use of NAC is seen in the sub selection of patients with nodal involvement (*N* = 9665); the use of NAC increased from 38% (*N* = 636) in 2012 to 61% (*N* = 1168) in 2016; for cT1N+ from 17% (*N* = 80) to 38% (*N* = 169), for cT2N+ from 35% (*N* = 289) to 63% (*N* = 613) and for cT3N+ from 67% (*N* = 159) to 80% (*N* = 283).

As presented in Table 1, 'BCS after NAC' increased from 43% in 2012 to 57% in 2016, which is a relative increase of 33%. For 'Primary BCS', an increased percentage of 63% in 2012 to 69% in 2016 is observed, which is a relative increase of only 9.5%. As depicted in Fig. 1A, an upward trend of 'BCS after NAC' for cT1N0 breast cancer is described from 43% (*N* = 20) to 61% (*N* = 99), for cT2N0 from 65% (*N* = 139) to 70% (*N* = 437) and for cT3N0 from 30% (*N* = 14) to 43%

Table 1
Clinical-pathological and hospital characteristics of patients with invasive cT1–4M0 breast cancer (N = 8195) who have received NAC followed by surgery (2012–2016).

	NAC + BCS (N = 4170)		NAC + Mastectomy (N = 4025)		
Year of incidence					
2012 (07-2011 – 06-2012)	424	43%	553	57%	<0,005
2013 (07-2012 – 06-2013)	626	47%	716	53%	
2014 (07-2013 – 06-2014)	836	50%	838	50%	
2015 (07-2014 – 06-2015)	1086	52%	1008	48%	
2016 (07-2015 – 06-2016)	1198	57%	910	43%	
Age					
<40	395	39%	626	61%	<0,005
40–50	1307	49%	1341	51%	
50–60	1462	55%	1173	45%	
60–70	872	55%	704	45%	
70–100	132	42%	181	58%	
Histologic subtype					
Ductal	3633	53%	3287	48%	<0,005
Lobular	331	41%	482	59%	
DCIS component					
No	2684	52%	2463	48%	0,009
Yes	1486	49%	1562	51%	
Clinical tumour stage					
cT1	706	59%	488	41%	<0,005
cT2	2948	63%	1763	37%	
cT3	442	26%	1246	74%	
cT4	74	12%	528	88%	
Clinical nodal stage					
cN0	1976	59%	1401	41%	<0,005
cN1	1921	47%	2164	53%	
cN2	80	38%	128	62%	
cN3	192	37%	329	63%	
Hormone receptor status					
Triple -	890	55%	743	45%	0,007
HR -, HER2+	338	48%	367	52%	
HR +, HER2+	610	54%	529	46%	
HR +, HER2-	2237	50%	2267	50%	
Type of hospital					
General-	1356	50%	1331	50%	0,016
Teaching-	1987	50%	2004	50%	
Academic-	827	55%	690	45%	
Hospital surgical volume					
<150	1043	51%	988	49%	0,472
150–300	1557	50%	1531	50%	
>300	1562	51%	1493	49%	

(N = 54). Shown in Fig. 1B, an equal upward trend of 'BCS after NAC' is seen in the sub selection of patients with nodal involvement; for cT1N+ from 58% (N = 46) to 69% (N = 116), for cT2N+ from 56% (N = 161) to 62% (N = 377) and for cT3N+ from 18% (N = 29) to 31% (N = 87). The group of cT4 breast cancer patients treated is too small for reliable analyses (N < 110 of patients treated with NAC per year).

For 'Primary BCS', increased percentages of more BCS per tumour stage is observed. However, this increase is to a lesser extent; from 76% to 80% for cT1N0, from 49% to 51% for cT2N0 and

from 6% to 11% for cT3N0. For patients with nodal involvement: from 51% to 58% for cT1N+, from 24% to 26% for cT2N+ and from 4% to 6% for cT3N+.

Surgical outcomes of BCS after NAC

Table 3 shows the surgical outcomes of 'BCS after NAC' in terms of focally or more than focally involved invasive margins and re-excision rates. Of all patients treated with BCS after NAC between 2011 and 2016 (N = 4170), 8,5% (n = 355) had focally involved

Table 2
Patients with invasive cT1–4M0 breast cancer who have received NAC followed by surgery, per tumour stage; 2012 compared to 2016.

	Total	NAC	%	Followed by surgery		No NAC	%	Primary surgery	
				BCS	Mastectomy			BCS	Mastectomy
2012									
cT1	6600	129	2%	52%	48%	6471	98%	74%	26%
cT2	3445	508	15%	60%	40%	2937	85%	44%	56%
cT3	475	216	45%	20%	80%	259	55%	5%	95%
cT4	197	124	63%	8%	92%	73	37%	8%	92%
cT1-4	10717	977	9%	43%	57%	9740	91%	63%	37%
2016									
cT1	7161	335	5%	65%	35%	6828	95%	79%	21%
cT2	3768	1271	33%	66%	34%	2526	67%	48%	52%
cT3	666	432	62%	35%	65%	256	38%	9%	91%
cT4	198	153	62%	19%	81%	75	38%	17%	83%
cT1-4	11793	153	18%	57%	43%	9685	82%	68%	32%



Fig. 1. a Trends in NAC followed by BCS per tumour stage in patients with cN0 disease; 2012–2016. *N = patients treated with NAC. b. Trends in NAC followed by BCS per tumour stage in patients with nodal involvement; 2012–2016. *N = patients treated with NAC.

invasive margins and 6,7% (n = 281) had more than focally involved invasive margins. The re-excision rate was 6,6%; consisting of

Table 3
Surgical outcomes of patients with invasive cT1-4M0 breast cancer who have received breast conserving surgery with or without chemotherapy upfront (2012–2016).

	NAC + BCS (N = 4170)		Primary BCS (N = 32.305)		
Involved margins (Invasive or DCIS)					
> focally	286	6,9%	1075	3,3%	<0,005
Focally	439	10,5%	3124	9,7%	
No	3391	81,3%	27994	86,7%	
Involved invasive margins					
> focally invasive	281	6,7%	1001	3,1%	<0,005
Focally invasive	355	8,5%	2021	6,3%	
No	3480	83,5%	29171	90,3%	
Involved DCIS margins^a					
> focally DCIS	32	2,3%	510	3,3%	0,107
Focally DCIS	126	9,1%	1423	9,3%	
No	1229	88,6%	13342	87,3%	
Re-excision					
No	3823	91,7%	29309	90,7%	<0,005
Yes	275	6,6%	1699	5,3%	
missing	72	1,7%	1297	4,0%	
Type of re-excision					
BCS	146	53,1%	933	54,9%	0,661
Mastectomy	129	46,9%	764	45,0%	

^a This is excl. patients with invasive cT1-4M0 breast cancer without DCIS involvement.

almost all patients with more than focally involved margins. For primary BCS (N = 32.305), these percentages are 6,3% and 3,1% respectively, resulting in a 5,3% overall re-excision rate. On multi-variable analysis, prognostic factors associated with involved invasive margins for both patients treated with primary BCS as for BCS after NAC are: lobular invasive breast cancer, an increasing clinical tumour stage and a hormone receptor positive receptor status (all p < 0,005; Table 4). The type of hospital, the year of incidence, a DCIS component and nodal involvement are only associated with involved invasive margins for primary BCS (all p < 0,005). From a sub-analysis on re-excision rates, lobular invasive breast cancer was the only significant factor associated with a mastectomy if a re-excision was performed because of involved margins in BCS after NAC.

As shown in Fig. 2, there is a significant difference in involved invasive margins (in terms of focally or more than focally) in patients treated with BCS after NAC compared to patients treated with primary BCS per tumour stage. While the percentage of involved invasive margins (IMR) for cT1 patients treated with BCS after NAC is higher than after primary BCS (12,3% compared to 8,3%; p < 0,005) and comparable for cT2 patients (14,0% compared to 13,7%; p = 0,046), the percentage of IMR is significant lower for cT3 patients treated with BCS after NAC compared to primary BCS (28,3% versus 31,0%; p < 0,005). When we analysed the data for cT3 patients, lobular invasive breast cancer and a hormone receptor positive receptor status were associated with IMR, with no difference between patients receiving NAC and patients receiving no NAC.

Table 4
Multivariable logistic regression for the odds of involved invasive margins in patients with invasive cT1–4M0 breast cancer who have received breast conserving surgery with or without chemotherapy upfront (2012–2016).

	NAC + BCS (N = 4116)				Primary BCS (N = 32.193)		
	OR	95% CI			OR	95% CI	
		Lower	Upper			Lower	Upper
Year of incidence				0,318			<0,005
2012	ref.						
2013	1,158	0,784	1,712	0,823	0,721	0,939	
2014	0,881	0,602	1,291	0,79	0,694	0,9	
2015	1,186	0,828	1,698	0,831	0,73	0,947	
2016	1,113	0,78	1,587	0,793	0,696	0,904	
Age				0,561			0,038
<40	0,912	0,62	1,343	0,977	0,703	1,359	
40–50	1,02	0,805	1,292	1,126	0,973	1,302	
50–60	ref.			ref.			
60–70	1,107	0,856	1,431	0,919	0,825	1,023	
70–100	0,649	0,335	1,258	1,05	0,939	1,174	
Histologic subtype				<0,005			<0,005
Ductal	ref.			ref.			
Lobular	4,684	3,559	6,165	2,912	2,602	3,259	
DCIS component				0,024			<0,005
No	ref.			ref.			
Yes	1,273	1,032	1,57	1,182	1,081	1,292	
Clinical tumor stage				<0,005			<0,005
cT1	ref.			ref.			
cT2	1,275	0,966	1,683	1,676	1,523	1,844	
cT3	2,622	1,837	3,744	3,202	1,853	5,532	
cT4	3,333	1,805	6,157	2,904	1,365	6,178	
Clinical nodal stage				0,017			<0,005
cN0	ref.			ref.			
cN1	1,291	1,054	1,581	1,664	1,419	1,952	
cN2	2,013	1,06	3,822	2,639	1,187	5,867	
cN3	1,49	0,928	2,393	4,776	1,736	13,138	
Hormone receptor status				<0,005			<0,005
Triple –	1,311	0,627	2,742	0,523	0,433	0,633	
HR –, HER2+	ref.	0,064	0,233	ref.	0,064	0,233	
HR +, HER2+	2,908	1,444	5,86	0,709	0,523	0,962	
HR +, HER2–	8,184	4,29	15,612	0,844	0,714	0,998	
Type of hospital				0,035			<0,005
General-	1,118	0,88	1,421	1,148	1,044	1,263	
Teaching-	ref.			ref.			
Academic-	1,405	1,086	1,817	1,254	1,085	1,449	
Hospital surgical volume				0,956			0,031
< 150	ref.			ref.			
150–300	0,986	0,752	1,294	1,029	0,921	1,151	
> 300	1,021	0,787	1,325	0,907	0,812	1,012	

Discussion

This population-based study showed an increase in the use of NAC from 9% in 2011 to 18% in 2016 and an increase of more 'BCS after NAC' from 43% to 57% compared to 'primary BCS' from 63% to 68% in patients with primary breast cancer in the Netherlands. The increasing implementation of NAC is consistent with previous studies on the trend of NAC in breast cancer care [22–24]. Together with this international trend, it is demonstrated that NAC increases the rates of breast preservation in tumours of >2 cm [25,26]. However, this study shows an increasing trend towards more BCS after NAC not only for larger tumours but for all stages of breast cancer.

There are several explanations for this upward trend towards more 'BCS after NAC' for all stages of disease. With the increased evidence that subgroups of patients who achieve a complete pathological tumour (pCR) after NAC do have a better prognosis in terms of disease-free and overall survival, NAC is nowadays be

considered as a preferred option in the treatment of triple negative and HER2+ breast cancer [27–29]. Secondly, the amount of a pCR response reported has increased dramatically in the past years because of improvements of targeted therapies. Up to half of the patients in specific groups such as her2-positive patients achieve a complete remission after NAC, which has subsequently led to more BCS [30–33]. Furthermore, the development of innovative approaches to axillary staging after chemotherapy has most likely contributed to more BCS followed by NAC in patients with nodal involvement at diagnosis [6,8,34,35]. Thereby, the growing experience and confidence with NAC among clinicians due to information from nationwide clinical quality registries, the use of quality indicators providing benchmark information on surgical outcomes and the exchange of knowledge by a multidisciplinary approach and cross-border hospital collaborations may all be attributed to the upward trend towards more BCS after NAC.

The involved invasive margin rate in our study is 6,7% for 'BCS after NAC' compared to 3,1% for 'primary BCS'. The overall positive




Fig. 2. Percentage of patients with invasive cT1–4M0 breast cancer and involved invasive margins who have received breast conserving surgery with or without chemotherapy upfront (2012–2016).

margin rate in our study is 6.9% for 'BCS after NAC' compared to 3.3% for 'primary BCS'. These rates are relatively low compared to other studies. In a systematic review performed by Volders et al. in which they aimed to determine surgical outcomes for BCS after NAC, involved margins ranged from 5% to 39.8% after NAC versus 13.1%–46% for primary BCS [36]. These percentages were based on ten studies describing involved margins with or without NAC, but a clear comparison between these studies was not possible due to variation in terminology and variation amongst patient groups. Because of the nationwide character of our study in which all patients treated with invasive breast cancer are included, a 6.9% involved margin rate for BCS after NAC and a 3.3% involved margin rate for primary BCS is a reliable baseline for the quality of care in the Netherlands nowadays.

An important result of this nationwide data is that BCS after NAC leads to equal surgical outcomes for cT2 and improved outcomes for cT3 invasive breast cancer compared to primary BCS. Boughey et al. already described in 2006 using data from 1998 to 2005, that NAC reduces the volume of tissue excised in patients with T2 and T3 breast cancer treated with BCS, without an increase in rates of re-excision [37]. Ever since, improvements of targeted therapies to achieve a pathologic complete response (pCR) in combination with improvements in the identification of the original tumour location have led to more BCS after NAC with less involved invasive margins and a lower re-operation rates [9–12,22].

Our multivariable analyses detailed important prognostic factors associated with a higher risk of involved invasive margins for patients who will receive BCS after NAC: lobular invasive breast cancer, an increasing clinical tumour stage and a hormone receptor positive receptor status. A decreased feasibility for successful BCS has been described in the setting of lobular histology, multicentricity and diffuse calcifications noted on preoperative mammography [38]. And, it is known that HR-positive subtypes are associated with the lowest rates of pathological complete response (pCR) [30]. Another interesting assumption made by Landscaper et al. is that cancer subtypes may have an independent association with a surgical outcome, reported that triple-negative patients not receiving NAC had the lowest reoperation rate. This result correlates with our findings that a positive hormone receptor status was clearly associated with involved invasive margins for cT3 tumours, with no difference between patients receiving NAC and patients

receiving no NAC. Because larger tumour size and higher grade are characteristics commonly reported on triple negative patients and because NAC is the standard of care for many of these patients [39], this will have contributed to the lower rate of involved margins for cT3 invasive breast cancer patients treated with NAC as seen in our study. Moreover, it supports the biologic heterogeneity of invasive breast cancer with its own approach and expected surgical outcomes.

Unaddressed issues are recurrence rates and cosmetic outcomes for patients treated with BCS after NAC, which we were unable to investigate in this study. A strong association of improved long-term outcomes in patients with pCR compared to patients with residual invasive tumour at the time of surgery has been consistently reported by many groups [11,30,40,41]. However, the surrogacy of pCR as an endpoint for long-term clinical outcome has not been established [42]. Future analyses of randomized trials of targeted agents in homogeneous tumour subtypes will help elucidate whether there is a significant association between pCR and long-term outcomes. Cosmetic outcomes for NAC followed by BCS have only been reported in retrospective studies and no conclusions can be drawn yet [43,44]. Several studies do describe a lower resected volume in patients treated with neoadjuvant therapy compared to adjuvant therapy, what potentially could lead to better cosmetic outcomes and an improved quality of life. Although we did not specify resection volumes and cosmetic outcome in this study, we emphasize the fact that follow-up on this subject is necessary and of major impact in delivering quality care to patients. A poor cosmetic outcome after BCS should be avoided at any time. Work has been established to link patient reported outcome measurements (PROMS) to clinical data of patients treated with BCS after NAC and will eventually show the patients' satisfaction and long term cosmetic outcomes. This information will be of great value empowering patients to be effective advocates for their health, and that they can make informed decisions in light of it.

To our knowledge, this is one of the largest studies on a nationwide level demonstrating a trend of more BCS after NAC in relation to surgical outcomes. However, our study is limited by the retrospective nature and incomplete information on tumour response after NAC. Also, we were unable to retrospectively

determine the percentage of patients eligible for BCS at the time of diagnosis.

Conclusion

The increasing implementation of NAC have led to an increase in 'BCS after NAC' in the Netherlands between 2011 and 2016. Moreover, this nationwide data confirms that BCS after NAC results in equal surgical outcomes for cT2 and improved surgical outcomes for cT3 invasive breast cancer compared to primary BCS. In view of the trend towards de-escalation of surgical treatment in selected patients with excellent pathologic response, these promising results confirm that clinicians are increasingly able to perform 'BCS after NAC' while maintaining good surgical outcomes.

Authors' contributions

All persons listed as authors were actively involved in one or more key aspects of the reported study. P.E.R.S. — conception, design and acquisition of data, and analysis and interpretation of data; drafting the article; final approval. J.H.V. — conception and design, and analysis and interpretation of data; revising critically; final approval. P.T. — interpretation of data; revising critically; final approval. C.H.S.— design; interpretation of data; revising critically; final approval. M.T.F.D.V.P.—design, interpretation of data; revising critically; final approval.

Conflict of interest

The authors declare that there is no conflict of interest.

Appendices

Table A

Clinical-pathological and hospital characteristics of cT1–4M0 breast cancer patients (N = 36,475) who have received breast conserving surgery with or without chemotherapy upfront (2012–2016).

	BCS (N = 32,305)		BCS after NAC (N = 4170)		
Year of incidence					
2012	6118	19%	424	10%	<0,005
2013	6466	20%	626	15%	
2014	6720	21%	836	20%	
2015	6368	20%	1086	26%	
2016	6633	21%	1198	29%	
Age					
<40	617	2%	395	9%	<0,005
40–50	3308	10%	1307	31%	
50–60	8787	27%	1462	35%	
60–70	10852	34%	872	21%	
70–100	8735	27%	132	3%	
Histologic subtype					
Ductal	26920	90%	3633	92%	<0,005
Lobular	2979	10%	331	8%	
DCIS component					
No	16487	51%	2684	64%	<0,005
Yes	15818	49%	1486	36%	
Clinical tumour stage					
cT1	26003	80%	706	17%	<0,005
cT2	6156	19%	2948	71%	
cT3	92	0%	442	11%	
cT4	54	0%	74	2%	
Clinical nodal stage					
cN0	30678	95%	1976	47%	<0,005

Table A (continued)

	BCS (N = 32,305)		BCS after NAC (N = 4170)		
cN1	1558	5%	1921	46%	
cN2	42	0%	80	2%	
cN3	26	0%	192	5%	
Hormone receptor status					
Triple -	2793	9%	890	22%	<0,005
HR -, HER2+	707	2%	338	8%	
HR +, HER2+	2113	7%	610	15%	
HR +, HER2-	25000	82%	2237	55%	
Type of hospital					
General-	12635	39%	1356	33%	<0,005
Teaching-	17019	53%	1987	48%	
Academic-	2651	8%	827	20%	
Hospital surgical volume					
<150	8635	27%	1043	25%	<0,005
150–300	12202	38%	1557	37%	
>300	11163	35%	1562	38%	

Table B

Clinical-pathological and hospital characteristics associated with tumour free margins in cT1–4M0 breast cancer patients who have received breast conserving surgery after neoadjuvant chemotherapy (N = 4116).

	No involved margins (N = 3835)		Involved margins (N = 281)		
Year of incidence					
2012	395	94%	25	6%	0,823
2013	567	93%	43	7%	
2014	777	94%	52	6%	
2015	1004	93%	74	7%	
2016	1092	93%	87	7%	
Age					
<40	377	96%	14	4%	0,017
40–50	1203	93%	86	7%	
50–60	1337	93%	108	7%	
60–70	791	92%	68	8%	
70–100	126	97%	4	3%	
Histologic subtype					
Ductal	3419	95%	169	5%	<0,005
Lobular	239	73%	87	27%	
DCIS component					
No	2473	93%	177	7%	0,606
Yes	1362	93%	104	7%	
Clinical tumour stage					
cT1	672	96%	27	4%	<0,005
cT2	2731	94%	177	6%	
cT3	367	84%	68	16%	
cT4	65	88%	9	12%	
Clinical nodal stage					
cN0	1837	94%	113	6%	0,024
cN1	1752	92%	145	8%	
cN2	69	87%	10	13%	
cN3	176	93%	13	7%	
Hormone receptor status					
Triple -	865	98%	16	2%	<0,005
HR -, HER2+	333	99%	3	1%	
HR +, HER2+	590	98%	15	2%	
HR +, HER2-	1958	89%	244	11%	
Type of hospital					
General-	1242	93%	90	7%	<0,005
Teaching-	1855	94%	113	6%	
Academic-	738	90%	78	10%	
Hospital surgical volume					
<150	950	93%	74	7%	0,672
150–300	1438	94%	98	6%	
>300	1440	93%	108	7%	

References

- [1] Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. *Ann Oncol* 1998;9(11):1179–84. <https://doi.org/10.1023/A:1008400706949>.
- [2] Killelea BK, Yang VQ, Mougalian S, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the national cancer database. *J Am Coll Surg* 2015;220(6):1063–9. <https://doi.org/10.1016/j.jamcollsurg.2015.02.011>.
- [3] Puig CA, Hoskin TL, Day CN, et al. National trends in the use of neoadjuvant chemotherapy for hormone receptor-negative breast cancer: a national cancer data base study. *Ann Surg Oncol* 2017;24(5):1242–50. <https://doi.org/10.1245/s10434-016-5733-y>.
- [4] Markopoulos C, Tsaroucha AK, Kouskos E, et al. Impact of breast cancer surgery on the self-esteem and sexual life of female patients. *J Int Med Res* 2009;37(1):182–8. <https://doi.org/10.1177/147323000903700122>.
- [5] Kim MK, Kim T, Moon HG, et al. Effect of cosmetic outcome on quality of life after breast cancer surgery. *Eur J Surg Oncol* 2015;41(3):426–32. <https://doi.org/10.1016/j.ejso.2014.12.002>.
- [6] Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. *J Clin Oncol* 2016;34(10):1072–8. <https://doi.org/10.1200/JCO.2015.64.0094>.
- [7] Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. *Ann Surg Oncol* 2016;23(11):3467–74. <https://doi.org/10.1245/s10434-016-5246-8>.
- [8] Van Der Noordaa MEM, Duijnhoven FH, Van Straver ME, et al. Major reduction in axillary lymph node dissections after neoadjuvant systemic therapy for node-positive breast cancer by combining PET/CT and the MARI procedure. *Ann Surg Oncol* 2018;25(6):1512–20. <https://doi.org/10.1245/s10434-018-6404-y>.
- [9] Schmitz AMT, Teixeira SC, Pengel KE, et al. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18 F-FDG PET/CT in breast cancer subtypes. *PLoS One* 2017;12(5):1–14. <https://doi.org/10.1371/journal.pone.0176782>.
- [10] Groheux D, Majdoub M, Sanna A, et al. Early metabolic response to neoadjuvant treatment: FDGPET/CT criteria according to breast cancer subtype. *Radiology* 2015;277(2):358–71. <https://doi.org/10.1148/radiol.2015141638>.
- [11] Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol* 2012;30(15):1796–804. <https://doi.org/10.1200/JCO.2011.38.8595>.
- [12] Houssami N, MacAskill P, Von Minckwitz G, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. *Eur J Surg Oncol* 2012;48(18):3342–54. <https://doi.org/10.1016/j.ejca.2012.05.023>.
- [13] Vrancken Peeters MJ. Towards omitting breast cancer surgery in patients without residual tumor after upfront chemotherapy [Nederlands Trial Register web site]. Available at: <http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=6120>. [Accessed 10 July 2018].
- [14] Kuerer HM, Peeters MTFD, Rea DW, et al. Nonoperative management for invasive breast cancer after neoadjuvant systemic therapy: conceptual basis and fundamental international feasibility clinical trials. *Ann Surg Oncol* 2017;24(10):2855–62. <https://doi.org/10.1245/s10434-017-5926-z>.
- [15] Van Der Noordaa MEM, Duijnhoven FH, Van Loo CE, et al. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: study design and feasibility of the MICRA trial. *Breast* 2018;23(40):76–81. <https://doi.org/10.1016/j.breast.2018.04.015>.
- [16] Biganzoli L, Marotti L, Hart CD, et al. Quality indicators in breast cancer care: an update from the EUSOMA working group. *Eur J Surg Oncol* 2017;86:59–81. <https://doi.org/10.1016/j.ejca.2017.08.017>.
- [17] Holmes D, Colfray A, Czerniecki B, et al. Performance and practice guideline for the use of neoadjuvant systemic therapy in the management of breast cancer. *Ann Surg Oncol* 2015;22(10):3184–90. <https://doi.org/10.1245/s10434-015-4753-3>.
- [18] Dutch national breast cancer guideline [Oncoline richtlijn version 2.0, 2012 web site]. Available at: <http://www.oncoline.nl/mammacarcinoom>. Accessed 10 July 2018.
- [19] Bommel ACM van, Spronk PER, Vrancken Peeters MJTFD, et al. Clinical auditing as an instrument for quality improvement in breast cancer care in The Netherlands: the national NABON Breast Cancer Audit. *J Surg Oncol* 2017;115(3):243–9. <https://doi.org/10.1002/jso.24516>.
- [20] Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. *Lancet Oncol* 2015;16(1):47–56. [https://doi.org/10.1016/S1470-2045\(14\)71156-8](https://doi.org/10.1016/S1470-2045(14)71156-8).
- [21] Primaire locoregionale behandeling van stadium I-II [Oncoline richtlijn 2008 web site]. Available from: http://www.oncoline.nl/index.php?pagina=/richtlijn/item/pagina.php&id=34705&richtlijn_id=828. Accessed 10 July 2018.
- [22] Landercasper J, Bennie B, Parsons BM, et al. Fewer reoperations after lumpectomy for breast cancer with neoadjuvant rather than adjuvant chemotherapy: a report from the national cancer database. *Ann Surg Oncol* 2017;24(6):1507–15. <https://doi.org/10.1245/s10434-016-5760-8>.
- [23] Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. *Cancer* 2015;121(15):2544–52. <https://doi.org/10.1002/cncr.29348>.
- [24] Clough KB, Acosta-marin V, Nos C, et al. Rates of neoadjuvant chemotherapy and oncoplastic surgery for breast cancer Surgery: a French national survey. *Ann Surg Oncol* 2015;22(11):3504–11. <https://doi.org/10.1245/s10434-015-4378-6>.
- [25] Killelea BK, Yang VQ, Mougalian S, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the national cancer database. *J Am Coll Surg* 2015;220(6):1063–9. <https://doi.org/10.1016/j.jamcollsurg.2015.02.011>.
- [26] Christy CJ, Thorsteinsson D, Grube BJ, et al. Preoperative chemotherapy decreases the need for Re-excision of breast cancers between 2 and 4 cm diameter. *Ann Surg Oncol* 2009;16(3):697–702. <https://doi.org/10.1245/s10434-008-0268-5>.
- [27] Spronk PER, Bommel ACM van, Siesling S, et al. Variation in use of neoadjuvant chemotherapy in patients with stage III breast cancer: results of the Dutch national breast cancer audit. *Breast* 2017;36:34–8. <https://doi.org/10.1016/j.breast.2017.08.011>.
- [28] Graham PJ, Brar MS, Foster T, et al. Neoadjuvant chemotherapy for breast cancer, is practice changing? A population-based review of current surgical trends. *Ann Surg Oncol* 2015;22(10):3376–82. <https://doi.org/10.1245/s10434-015-4714-x>.
- [29] Gnant M, Thomssen C, Harbeck N, et al. St. Gallen/Vienna 2015: a brief summary of the consensus discussion. *Breast Care* 2015;10(2):124–30. <https://doi.org/10.1159/000430488>.
- [30] Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet* 2014;384(9938):164–72. [https://doi.org/10.1016/S0140-6736\(13\)62422-8](https://doi.org/10.1016/S0140-6736(13)62422-8).
- [31] SABCS 2015: Pathologic Complete Response To Presurgery Chemotherapy Improves Survival For Patients With Triple-Negative Breast Cancer. Available at: <http://www.ascp.org/News/34135>. Accessed 5 April 2018.
- [32] Ramshorst MS, Loo MH der, Dackus GMHE, et al. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. *Breast Canc Res Treat* 2016;158(2):361–71. <https://doi.org/10.1007/s10549-016-3878-9>.
- [33] Ramshorst MS van, Werkhoven E van, Mandjes IAM, et al. Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: the TRAIN-study. *Eur J Surg Oncol* 2017;74:47–54. <https://doi.org/10.1016/j.ejca.2016.12.023>.
- [34] Koolen BB, Donker M, Straver ME, et al. Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant. *Br J Surg* 2017;104(9):1188–96. <https://doi.org/10.1002/bjs.10555>.
- [35] Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. *Ann Surg* 2015;261(2):378–82. <https://doi.org/10.1097/SLA.0000000000000558>.
- [36] Volders JH, Negenborn VL, Spronk PER, et al. Breast-conserving surgery following neoadjuvant therapy - a systematic review on surgical outcomes. *Breast Canc Res Treat* 2018;168(1):1–12. <https://doi.org/10.1007/s10549-017-4598-5>.
- [37] Boughay JC, Peintinger F, Meric-Bernstam F, et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. *Ann Surg* 2006;244(3):464–70. <https://doi.org/10.1097/01.sla.0000234897.38950.5c>.
- [38] Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. *Ann Surg Oncol* 2002;9(3):228–34.
- [39] Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. *Mod Pathol* 2006;19:264–71. <https://doi.org/10.1038/modpathol.3800528>.
- [40] Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. *J Clin Oncol* 2007;25(28):4414–22. <https://doi.org/10.1200/JCO.2007.10.6823>.
- [41] Von Minckwitz G, Untch M, Nüesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. *Breast Canc Res Treat* 2011;125(1):145–56. <https://doi.org/10.1007/s10549-010-1228-x>.
- [42] Cortazar P, Geyer Jr CE. Pathological complete response in neoadjuvant treatment of breast cancer. *Ann Surg Oncol* 2015;22:1441–6. <https://doi.org/10.1245/s10434-015-4404-8>.
- [43] Immink JM, Putter H, Bartelink H, et al. Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC “boost versus no boost” trial. *Ann Oncol* 2012;23(10):2591–8. <https://doi.org/10.1093/annonc/mds066>.
- [44] Hennigs A, Hartmann B, Rauch G, et al. Long-term objective esthetic outcome after breast-conserving therapy. *Breast Canc Res Treat* 2015;153(2):345–51. <https://doi.org/10.1007/s10549-015-3540-y>.